|
1
|
Bray F, Ferlay J, Soerjomataram I, Siegel
RL, Torre LA and Jemal A: Global cancer statistics 2018: GLOBOCAN
estimates of incidence and mortality worldwide for 36 cancers in
185 countries. CA Cancer J Clin. 68:394–424. 2018. View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Kanwal M, Ding XJ, Song X, Zhou GB and Cao
Y: MUC16 overexpression induced by gene mutations promotes lung
cancer cell growth and invasion. Oncotarget. 9:12226–12239. 2018.
View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Subramanian J, Velcheti V, Gao F and
Govindan R: Presentation and stage-specific outcomes of lifelong
never-smokers with non-small cell lung cancer (NSCLC). J Thorac
Oncol. 2:827–830. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Arnheim N and Calabrese P: Understanding
what determines the frequency and pattern of human germline
mutations. Nat Rev Genet. 10:478–488. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Tang XN, Shigematsu H, Bekele BN, Roth JA,
Minna JD, Hong WK, Gazdar AF and Wistuba II: EGFR tyrosine kinase
domain mutations are detected in histologically normal respiratory
epithelium in lung cancer patients. Cancer Res. 65:7568–7572. 2005.
View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Arteaga CL: EGF receptor mutations in lung
cancer: From humans to mice and maybe back to humans. Cancer Cell.
9:421–423. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Yu HA, Arcila ME, Hellmann MD, Kris MG,
Ladanyi M and Riely GJ: Poor response to erlotinib in patients with
tumors containing baseline EGFR T790M mutations found by routine
clinical molecular testing. Ann Oncol. 25:423–428. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Oxnard GR, Miller VA, Robson ME, Azzoli
CG, Pao W, Ladanyi M and Arcila ME: Screening for germline EGFR
T790M mutations through lung cancer genotyping. J Thorac Oncol.
7:1049–1052. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Gazdar A, Robinson L, Oliver D, Xing C,
Travis WD, Soh J, Toyooka S, Watumull L, Xie Y, Kernstine K and
Schiller JH: Hereditary lung cancer syndrome targets never smokers
with germline EGFR gene T790M mutations. J Thorac Oncol. 9:456–463.
2014. View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Girard N, Lou E, Azzoli CG, Reddy R,
Robson M, Harlan M, Orlow I, Yatabe Y, Nafa K, Ladanyi M, et al:
Analysis of genetic variants in never-smokers with lung cancer
facilitated by an Internet-based blood collection protocol: A
preliminary report. Clin Cancer Res. 16:755–763. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Vikis H, Sato M, James M, Wang D, Wang Y,
Wang M, Jia D, Liu Y, Bailey-Wilson JE, Amos CI, et al: EGFR-T790M
is a rare lung cancer susceptibility allele with enhanced kinase
activity. Cancer Res. 67:4665–4670. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Amos CI, Gorlov IP, Dong Q, Wu X, Zhang H,
Lu EY, Scheet P, Greisinger AJ, Mills GB and Spitz MR: Nicotinic
acetylcholine receptor region on chromosome 15q25 and lung cancer
risk among African Americans: A case-control study. J Natl Cancer
Inst. 102:1199–1205. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Yi D, Xu L, Luo J, You X, Huang T, Zi Y,
Li X, Wang R, Zhong Z, Tang X, et al: Germline TP53 and MSH6
mutations implicated in sporadic triple-negative breast cancer
(TNBC): A preliminary study. Hum Genomics. 13:42019. View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Lu S, Yu Y, Li Z, Yu R, Wu X, Bao H, Ding
Y, Shao YW and Jian H: EGFR and ERBB2 germline mutations in Chinese
lung cancer patients and their roles in genetic susceptibility to
cancer. J Thorac Oncol. 14:732–736. 2019. View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Mäkinen N, Zhou M, Bemus M, Nevin J, Nag
A, Chen R, Colson YL, Thorner AR, Oxnard GR, Meyerson M and Sholl
LM: Genomic evolution in a patient with lung adenocarcinoma with a
germline EGFR T790M mutation. JTO Clin Res Rep.
2:1001462021.PubMed/NCBI
|
|
16
|
Bell DW, Gore I, Okimoto RA, Godin-Heymann
N, Sordella R, Mulloy R, Sharma SV, Brannigan BW, Mohapatra G,
Settleman J and Haber DA: Inherited susceptibility to lung cancer
may be associated with the T790M drug resistance mutation in EGFR.
Nat Genet. 37:1315–1316. 2005. View
Article : Google Scholar : PubMed/NCBI
|
|
17
|
Prudkin L, Tang X and Wistuba II:
Germ-line and somatic presentations of the EGFR T790M mutation in
lung cancer. J Thorac Oncol. 4:139–141. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Tibaldi C, Giovannetti E, Vasile E,
Boldrini L, Gallegos-Ruiz MI, Bernardini I, Incensati R, Danesi R,
Cappuzzo F, Peters GJ and Fontanini G: Inherited germline T790M
mutation and somatic epidermal growth factor receptor mutations in
non-small cell lung cancer patients. J Thorac Oncol. 6:395–396.
2011. View Article : Google Scholar : PubMed/NCBI
|
|
19
|
Shih JY, Gow CH, Yu CJ, Yang CH, Chang YL,
Tsai MF, Hsu YC, Chen KY, Su WP and Yang PC: Epidermal growth
factor receptor mutations in needle biopsy/aspiration samples
predict response to gefitinib therapy and survival of patients with
advanced nonsmall cell lung cancer. Int J Cancer. 118:963–969.
2006. View Article : Google Scholar : PubMed/NCBI
|
|
20
|
Ikeda K, Nomori H, Mori T, Sasaki J and
Kobayashi T: Novel germline mutation: EGFR V843I in patient with
multiple lung adenocarcinomas and family members with lung cancer.
Ann Thorac Surg. 85:1430–1432. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
21
|
Ohtsuka K, Ohnishi H, Kurai D, Matsushima
S, Morishita Y, Shinonaga M, Goto H and Watanabe T: Familial lung
adenocarcinoma caused by the EGFR V843I germ-line mutation. J Clin
Oncol. 29:e191–e192. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
22
|
Matsushima S, Ohtsuka K, Ohnishi H,
Fujiwara M, Nakamura H, Morii T, Kishino T, Goto H and Watanabe T:
V843I, a lung cancer predisposing EGFR mutation, is responsible for
resistance to EGFR tyrosine kinase inhibitors. J Thorac Oncol.
9:1377–1384. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
23
|
Demierre N, Zoete V, Michielin O, Stauffer
E, Zimmermann DR, Betticher DC and Peters S: A dramatic lung cancer
course in a patient with a rare EGFR germline mutation exon 21
V843I: Is EGFR TKI resistance predictable? Lung Cancer. 80:81–84.
2013. View Article : Google Scholar : PubMed/NCBI
|
|
24
|
Prim N, Legrain M, Guerin E, Mennecier B,
Weingertner N, Voegeli AC, Guenot D, Maugard CM, Quoix AE and
Beau-Faller M: Germ-line exon 21 EGFR mutations, V843I and P848L,
in nonsmall cell lung cancer patients. Eur Respir Rev. 23:390–392.
2014. View Article : Google Scholar : PubMed/NCBI
|
|
25
|
Song H, Chen Y, Yan Z, Sun G and Shi Z:
Response to osimertinib in a NSCLC patient harboring EGFR V843I
germ-line mutation. Lung Cancer. 150:247–248. 2020. View Article : Google Scholar : PubMed/NCBI
|
|
26
|
van Noesel J, van der Ven WH, van Os TAM,
Kunst PWA, Weegenaar J, Reinten RJA, Kancha RK, Duyster J and van
Noesel CJ: Activating germline R776H mutation in the epidermal
growth factor receptor associated with lung cancer with squamous
differentiation. J Clin Oncol. 31:e161–e164. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
27
|
Guo T, Zhu L, Li W, Lin R, Ding Y, Kang Q,
Shao L, Li C and Pan X: Two cases of non-small cell lung cancer
patients with somatic or germline EGFR R776H mutation. Lung Cancer.
161:94–97. 2021. View Article : Google Scholar : PubMed/NCBI
|
|
28
|
de Gunst MM, Gallegos-Ruiz MI, Giaccone G
and Rodriguez JA: Functional analysis of cancer-associated EGFR
mutants using a cellular assay with YFP-tagged EGFR intracellular
domain. Mol Cancer. 6:562007. View Article : Google Scholar : PubMed/NCBI
|
|
29
|
Lin X, Peng M, Chen Q, Yuan M, Chen R,
Deng H, Deng J, Liu O, Weng Y, Chen M and Zhou C: Identification of
the unique clinical and genetic features of chinese lung cancer
patients with EGFR germline mutations in a large-scale
retrospective study. Front Oncol. 11:7741562021. View Article : Google Scholar : PubMed/NCBI
|
|
30
|
Borràs E, Jurado I, Hernan I, Gamundi MJ,
Dias M, Martí I, Mañé B, Arcusa A, Agúndez JA, Blanca M and
Carballo M: Clinical pharmacogenomic testing of KRAS, BRAF and EGFR
mutations by high resolution melting analysis and ultra-deep
pyrosequencing. BMC Cancer. 11:4062011. View Article : Google Scholar : PubMed/NCBI
|
|
31
|
Han B, Zhou X, Zhang RX, Zang WF, Chen ZY,
Song HD, Wan HY and Zheng CX: Mutations of the epidermal growth
factor receptor gene in NSCLC patients. Oncol Lett. 2:1233–1237.
2011. View Article : Google Scholar : PubMed/NCBI
|
|
32
|
Klughammer B, Brugger W, Cappuzzo F,
Ciuleanu T, Mok T, Reck M, Tan EH, Delmar P, Klingelschmitt G, Yin
AY, et al: Examining treatment outcomes with erlotinib in patients
with advanced non-small cell lung cancer whose tumors harbor
uncommon EGFR mutations. J Thorac Oncol. 11:545–555. 2016.
View Article : Google Scholar : PubMed/NCBI
|
|
33
|
Sarcar B, Gimbrone NT, Wright G, Remsing
Rix LL, Gordian ER, Rix U, Chiappori AA, Reuther GW,
Santiago-Cardona PG, Muñoz-Antonia T and Cress WD: Characterization
of epidermal growth factor receptor (EGFR) P848L, an unusual EGFR
variant present in lung cancer patients, in a murine Ba/F3 model.
FEBS Open Bio. 9:1689–1704. 2019. View Article : Google Scholar : PubMed/NCBI
|
|
34
|
Yang J, Li H, Li B, Li W, Guo Q, Hu L,
Song Z and Zhou B: Profiling oncogenic germline mutations in
unselected chinese lung cancer patients. Front Oncol.
11:6475982021. View Article : Google Scholar : PubMed/NCBI
|
|
35
|
Shukuya T and Takahashi K: Germline
mutations in lung cancer. Respir Investig. 57:201–206. 2019.
View Article : Google Scholar : PubMed/NCBI
|
|
36
|
Nachman MW and Crowell SL: Estimate of the
mutation rate per nucleotide in humans. Genetics. 156:297–304.
2000. View Article : Google Scholar : PubMed/NCBI
|
|
37
|
Lu C, Xie M, Wendl MC, Wang J, McLellan
MD, Leiserson MD, Huang KL, Wyczalkowski MA, Jayasinghe R, Banerjee
T, et al: Patterns and functional implications of rare germline
variants across 12 cancer types. Nat Commun. 6:100862015.
View Article : Google Scholar : PubMed/NCBI
|
|
38
|
Huang KL, Mashl RJ, Wu Y, Ritter DI, Wang
J, Oh C, Paczkowska M, Reynolds S, Wyczalkowski MA, Oak N, et al:
Pathogenic germline variants in 10,389 adult cancers. Cell.
173:355–370.e14. 2018. View Article : Google Scholar : PubMed/NCBI
|
|
39
|
Wang Y, McKay JD, Rafnar T, Wang Z,
Timofeeva MN, Broderick P, Zong X, Laplana M, Wei Y, Han Y, et al:
Rare variants of large effect in BRCA2 and CHEK2 affect risk of
lung cancer. Nat Genet. 46:736–741. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
40
|
Peng W, Li B, Li J, Chang L, Bai J, Yi Y,
Chen R, Zhang Y, Chen C, Pu X, et al: Clinical and genomic features
of Chinese lung cancer patients with germline mutations. Nat
Commun. 13:12682022. View Article : Google Scholar : PubMed/NCBI
|
|
41
|
Choi SK, Yoon SR, Calabrese P and Arnheim
N: A germ-line-selective advantage rather than an increased
mutation rate can explain some unexpectedly common human disease
mutations. Proc Natl Acad Sci USA. 105:10143–10148. 2008.
View Article : Google Scholar : PubMed/NCBI
|
|
42
|
Tiemann-Boege I, Navidi W, Grewal R, Cohn
D, Eskenazi B, Wyrobek AJ and Arnheim N: The observed human sperm
mutation frequency cannot explain the achondroplasia paternal age
effect. Proc Natl Acad Sci USA. 99:14952–14957. 2002. View Article : Google Scholar : PubMed/NCBI
|
|
43
|
Kan SH, Elanko N, Johnson D,
Cornejo-Roldan L, Cook J, Reich EW, Tomkins S, Verloes A, Twigg SR,
Rannan-Eliya S, et al: Genomic screening of fibroblast
growth-factor receptor 2 reveals a wide spectrum of mutations in
patients with syndromic craniosynostosis. Am J Hum Genet.
70:472–486. 2002. View
Article : Google Scholar : PubMed/NCBI
|
|
44
|
Qin J, Calabrese P, Tiemann-Boege I,
Shinde DN, Yoon SR, Gelfand D, Bauer K and Arnheim N: The molecular
anatomy of spontaneous germline mutations in human testes. PLoS
Biol. 5:e2242007. View Article : Google Scholar : PubMed/NCBI
|
|
45
|
Crow JF: Age and sex effects on human
mutation rates: An old problem with new complexities. J Radiat Res.
47 (Suppl B):B75–B82. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
46
|
Malter HE, Iber JC, Willemsen R, de Graaff
E, Tarleton JC, Leisti J, Warren ST and Oostra BA: Characterization
of the full fragile X syndrome mutation in fetal gametes. Nat
Genet. 15:165–169. 1997. View Article : Google Scholar : PubMed/NCBI
|
|
47
|
Moutou C, Vincent MC, Biancalana V and
Mandel JL: Transition from premutation to full mutation in fragile
X syndrome is likely to be prezygotic. Hum Mol Genet. 6:971–979.
1997. View Article : Google Scholar : PubMed/NCBI
|
|
48
|
Silveira I, Alonso I, Guimarães L,
Mendonça P, Santos C, Maciel P, Fidalgo De Matos JM, Costa M,
Barbot C, Tuna A, et al: High germinal instability of the (CTG)n at
the SCA8 locus of both expanded and normal alleles. Am J Hum Genet.
66:830–840. 2000. View
Article : Google Scholar : PubMed/NCBI
|
|
49
|
Delatycki MB, Paris D, Gardner RJ, Forshaw
K, Nicholson GA, Nassif N, Williamson R and Forrest SM: Sperm DNA
analysis in a Friedreich ataxia premutation carrier suggests both
meiotic and mitotic expansion in the FRDA gene. J Med Genet.
35:713–716. 1998. View Article : Google Scholar : PubMed/NCBI
|
|
50
|
De Temmerman N, Sermon K, Seneca S, De
Rycke M, Hilven P, Lissens W, Van Steirteghem A and Liebaers I:
Intergenerational instability of the expanded CTG repeat in the
DMPK gene: Studies in human gametes and preimplantation embryos. Am
J Hum Genet. 75:325–329. 2004. View
Article : Google Scholar : PubMed/NCBI
|
|
51
|
Moseley ML, Schut LJ, Bird TD, Koob MD,
Day JW and Ranum LP: SCA8 CTG repeat: En masse contractions in
sperm and intergenerational sequence changes may play a role in
reduced penetrance. Hum Mol Genet. 9:2125–1230. 2000. View Article : Google Scholar : PubMed/NCBI
|
|
52
|
De Michele G, Cavalcanti F, Criscuolo C,
Pianese L, Monticelli A, Filla A and Cocozza S: Parental gender,
age at birth and expansion length influence GAA repeat
intergenerational instability in the X25 gene: Pedigree studies and
analysis of sperm from patients with Friedreich's ataxia. Hum Mol
Genet. 7:1901–1906. 1998. View Article : Google Scholar : PubMed/NCBI
|
|
53
|
Hultén MA, Patel SD, Westgren M,
Papadogiannakis N, Jonsson AM, Jonasson J and Iwarsson E: On the
paternal origin of trisomy 21 Down syndrome. Mol Cytogenet.
3:42010. View Article : Google Scholar : PubMed/NCBI
|
|
54
|
Li N, Liu C, Xiong L, Huang D and Jiang Y:
Pedigree analysis of the EGFR p.V1010M germline mutation in a
family with a family history of non-small-cell lung cancer. Ann
Transl Med. 10:1542022. View Article : Google Scholar : PubMed/NCBI
|
|
55
|
van der Leest C, Wagner A, Pedrosa RM,
Aerts JG, Dinjens WNM and Dubbink HJ: Novel EGFR V834L germline
mutation associated with familial lung adenocarcinoma. JCO Precis
Oncol. 2:PO.17.00266. 2018.PubMed/NCBI
|
|
56
|
Trabelsi Grati O, Zemoura L, Nhy C, Daniel
C, Melaabi S, Callens C, Gauthier Villars M, Bièche I and Girard N:
Long response to immune checkpoint inhibitors in metastatic NSCLC
despite EGFR germline mutation. A case report. Lung Cancer.
174:186–187. 2022. View Article : Google Scholar : PubMed/NCBI
|
